The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of BPM 31510 on survival outcomes when used in combination with gemcitabine in a preclinical model of pancreatic cancer.
Joaquin J. Jimenez
Consultant or Advisory Role - Berg Pharma
Stock Ownership - Berg Pharma
Research Funding - Berg Pharma
Lucia M Mauro
No relevant relationships to disclose
Viacheslav R Akmaev
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
John McCook
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
Min Du
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
Shen Luan
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
Paul Y. Song
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
Rangaprasad Sarangarajan
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma
Niven R Narain
Employment or Leadership Position - Berg Pharma
Stock Ownership - Berg Pharma